Home Tags Landmark at Eastview

Tag: Landmark at Eastview

Greenburgh approves Regeneron’s planned 1 million-square-foot expansion

The Greenburgh town board approved the company’s site plan application earlier this month.

Regeneron will pay $720M for Landmark at Eastview HQ campus

The state's largest biotechnology company has agreed to purchase its Westchester headquarters campus from its landlord, Biomed Realty.

Regeneron plans 1 million-square-foot expansion in Greenburgh

The biotechnology company plans to develop the research and development campus on a 100-acre vacant parcel adjacent to its headquarters at Landmark at Eastview.

Regeneron expands again at Landmark at Eastview

The state's largest biotechnology employer adds about 116,00 square feet of space in two buildings at its Westchester headquarters.

Landmark at Eastview property gets rezoning approval

The Landmark at Eastview property in Greenburgh receives unanimous rezoning approval from the town board.

Eastview property moves ahead in rezoning process

The Greenburgh town board holds a public hearing on plans to develop 100 acres as part of a biotech business hub.

Landmark at Eastview project moves closer to rezoning

The town of Greenburgh concludes its environmental review of a proposed rezoning that will pave the way for a large-scale development.

Landmark at Eastview project takes step forward

A biotech project is passed on from Greenburgh government to the Planning Board, a significant step forward on the road to construction.

Regeneron grows and celebrates success

The state’s largest biotechnology employer plans to add 400 jobs at its expanded headquarters in Westchester.

LCOR proposal moves forward in Greenburgh

A proposal for 411,450 square-feet of retail with a 110-room hotel is being considered in Greenburgh

Regeneron to expand in Westchester, add 400 jobs

Regeneron Pharmaceuticals Inc. expects to create more than 400 new jobs as part of an expansion of its Mount Pleasant corporate headquarters and laboratories, the company announced today.

Biotech company downsizes in Greenburgh

Progenics Pharmaceuticals announced a companywide restructuring after federal officials failed to approve an expanded use for its first commercial drug.

Progenics reports $10.7m loss as revenue falls by $73m

Progenics said the loss was due to decreased revenue from its collaboration with Salix Pharmaceuticals, which has the development and marketing rights to Progenics’ first commercial product, Relistor.